UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The quantitative assessment of body iron

Blood, 2003-05, Vol.101 (9), p.3359-3364

2003

Volltextzugriff (PDF)

Serum transferrin receptor

American journal of hematology, 2008-11, Vol.83 (11), p.872-875

Skikne, Barry S.

2008

Volltextzugriff (PDF)

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

Leukemia, 2018-12, Vol.32 (12), p.2546-2557

2018

Volltextzugriff (PDF)

A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura

Transfusion (Philadelphia, Pa.), 2006-10, Vol.46 (10), p.1693-1704

2006

Volltextzugriff (PDF)

Chronic myeloid leukaemia, BCR‐ABL1‐positive, in accelerated phase with marked eosinophilia with eosinophil atypia

British journal of haematology, 2020-03, Vol.188 (5), p.599-599

2020

Volltextzugriff (PDF)

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

American journal of hematology, 2018-10, Vol.93 (10), p.1199-1206

2018

Volltextzugriff (PDF)

Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index

American journal of hematology, 2011-11, Vol.86 (11), p.923-927

2011

Volltextzugriff (PDF)

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia

Leukemia research, 2018-09, Vol.72, p.79-85

2018

Volltextzugriff (PDF)

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

Biology of blood and marrow transplantation, 2018-10, Vol.24 (10), p.2017-2024

2018

Volltextzugriff (PDF)

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes

British journal of haematology, 2014-04, Vol.165 (1), p.49-56

2014

Volltextzugriff (PDF)

Oral and Parenteral Glutamine in Bone Marrow Transplantation: A Randomized, Double-Blind Study

JPEN. Journal of parenteral and enteral nutrition, 1999-05, Vol.23 (3), p.117-122

1999

Volltextzugriff (PDF)

Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura

Annals of hematology, 2005-04, Vol.84 (4), p.232-235

2005

Volltextzugriff (PDF)

Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.1971-1971

2023

Volltextzugriff (PDF)

Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics

Blood, 2023-11, Vol.142 (Supplement 1), p.1985-1985

2023

Volltextzugriff (PDF)

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.6900-6900

2023

Volltextzugriff (PDF)

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Blood, 2019-11, Vol.134 (Supplement_1), p.3605-3605

2019

Volltextzugriff (PDF)

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Blood, 2023-11, Vol.142 (Supplement 1), p.1582-1582

2023

Volltextzugriff (PDF)

Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience

Leukemia research, 2007-09, Vol.31 (9), p.1253-1257

2007

Volltextzugriff (PDF)

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Blood, 2019-11, Vol.134 (Supplement_1), p.5743-5743

2019

Volltextzugriff (PDF)

Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis

Blood, 2017-12, Vol.130, p.5541-5541

2017

Volltextzugriff (PDF)

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Blood, 2019-11, Vol.134 (Supplement_1), p.4236-4236

2019

Volltextzugriff (PDF)

Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S373-S373

2024

Volltextzugriff (PDF)

Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Blood, 2017-12, Vol.130, p.4512-4512

2017

Volltextzugriff (PDF)

Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response

Annals of hematology, 2005-08, Vol.84 (8), p.526-531

2005

Volltextzugriff (PDF)

Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies

Blood, 2015-12, Vol.126 (23), p.1680-1680

2015

Volltextzugriff (PDF)

1 – 25 von 154

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(144)
Mit Volltextzugriff
(131)

Publikationsform

Artikel
(153)
magazinearticle
(1)

Sprache

Englisch
(154)

Erscheinungsjahr

n.n

Thema

Humans
(73)
Science & Technology
(73)
Life Sciences & Biomedicine
(72)
Female
(42)
Hematology
(42)
Male
(39)
Middle Aged
(38)
Adult
(37)
Biological And Medical Sciences
(37)
Medical Sciences
(32)
Aged
(23)
Hematologic And Hematopoietic Diseases
(17)
Acute Myeloid Leukemia
(16)
Oncology
(16)
Aged, 80 And Over
(14)
Azacitidine - Therapeutic Use
(14)
Ferritins - Blood
(13)
Administration, Oral
(11)
Iron - Metabolism
(11)
Leukemia, Myeloid, Acute - Drug Therapy
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The quantitative assessment of body iron

Serum transferrin receptor

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura

Chronic myeloid leukaemia, BCR‐ABL1‐positive, in accelerated phase with marked eosinophilia with eosinophil atypia

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes

Oral and Parenteral Glutamine in Bone Marrow Transplantation: A Randomized, Double-Blind Study

Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura

Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy

Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response

Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies

Suchergebnisse filtern